Company intelligence / Profile preview

Medality Medical

Midland Park, New Jersey, United Statesmedalitymedical.com ↗

Ownership: Private
Development stage: Other

Overview

Medality Medical has developed the HydraSolve T2D™ Visceral Fat Extraction System, a patented surgical device designed to remove mesenteric visceral fat in overweight/obese patients with type 2 diabetes who have not achieved glycemic control on oral medications. The system aims to improve blood glucose control and insulin resistance. First-in-human clinical trials began after IRB approval at UT Health San Antonio in late 2019; further results are not publicly detailed as of June 2025.

Therapeutic areas: Endocrinology
Modalities: DeviceSurgical procedure/technology
Industry: Surgical Medical Devices

Partnerships

Clinical collaboration with University of Texas Health Science Center at San Antonio for human trials.

Beyond the preview

Go deeper on Medality Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medality Medical.

Explore the full profile